Medtronic plc MDT
At closeNov 6, 2026, 7:33 PM EST
After hours · Nov 6, 7:33 PM ET
- YTD
- +5.98%
- 1 year
- +13.04%
- Market cap
- 130.22B
- Revenue (ttm)
- 37.54B
- Profit margin
- 13.93%
- EPS (ttm)
- 4.07
- Shares out
- 1.28B
- P/E ratio
- 25.01
- Forward P/E
- 15.89
- Dividend
- 2.88 (2.75%)
- Ex-dividend date
- Sep 24, 2026
- YTD return
- +5.98%
- 1-year return
- +13.04%
- Volume
- 7.45M
- Avg volume
- 16.53M
- Open
- 101.54
- Previous close
- 104.84
- Day's range
- 100.80 – 103.07
- 52-week range
- 73.75 – 105.35
- Beta
- 0.57
- Analysts
- Buy
- Price target
- 104.62 (+2.8%)
- Earnings date
- Nov 24, 2026
5D +4.89 (+5.05%)
Key statistics
- Enterprise value
- 154.06B
- PEG ratio
- 1.88
- Price / sales
- 3.47
- Price / book
- 2.59
- Dividend yield
- 2.75%
- Payout ratio
- 70.02%
- Revenue growth
- 13.70%
- Free cash flow
- 5.41B
- Total cash
- 8.82B
- Total debt
- 28.15B
- Return on equity
- 10.65%
- Short % of float
- 10.89%
- 50-day average
- 92.47
- 200-day average
- 88.23
Analyst view
Consensus: buy
- Target (low)
- 85.00
- Target (mean)
- 104.62
- Target (high)
- 121.00
- Strong buy3
- Buy17
- Hold10
- Sell0
- Strong sell0
Next earnings
Nov 24, 2026
Expected Nov 24, 2026. Consensus EPS estimate 1.33.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 24, 2026 | Oct 31, 2026 | 1.33 | — | — | — |
| Sep 1, 2026 | Jul 31, 2026 | 1.39 | 1.45 | +0.06 | +4.32% |
| Jun 3, 2026 | Apr 24, 2026 | 1.54 | 1.55 | +0.01 | +0.65% |
| Feb 17, 2026 | Jan 23, 2026 | 1.34 | 1.36 | +0.02 | +1.49% |
| Nov 18, 2025 | Oct 24, 2025 | 1.31 | 1.36 | +0.05 | +3.82% |
| Aug 19, 2025 | Jul 25, 2025 | 1.23 | 1.26 | +0.03 | +2.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | BTIG | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Sep 30, 2026 | TD Cowen | reit | Buy | Buy |
| Sep 3, 2026 | UBS | main | Buy | Buy |
| Sep 2, 2026 | Truist Securities | reit | Hold | Hold |
| Sep 2, 2026 | Wells Fargo | main | Overweight | Overweight |
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Ireland
- Website
- medtronic.com
News
Medtronic to announce financial results for its second quarter of fiscal year 2027 
These 12 stocks are good bets to beat the 10-year Treasury over the next decade 
TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study 
Medtronic PLC $MDT Stock: Heritage Investors Management Corp Reduces Stake 
Hennessy Advisors Inc. Sells 31,426 Shares of Medtronic PLC $MDT 
Medtronic (MDT) Ascends While Market Falls: Some Facts to Note 
The Best Dividend Stocks to Buy With $5,000 in November 
Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy? 
Medtronic Announces Real-World Registry Results For Its Affera Mapping And Ablation System With The Sphere-9 Catheter And The PulseSelect Pulsed Field Ablation System; Analyses Report Strong Safety And Procedural Outcomes Across Atrial And Ventricular Arrhythmias 
MiniMed Names Kevin E. Lofton Board Chair, Effective Separation From Medtronic
Your note
Sign in to keep a note on MDT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNOLD CRAIG | Director | Stock Award(Grant) | Apr 26, 2026 | 42,185 |
| CORONA GARY LOUIS | Chief Financial Officer | Stock Award(Grant) | Jan 20, 2025 | 44,255 |
| HOGAN RANDALL J III | Director | Stock Award(Grant) | Apr 26, 2026 | 48,998 |
| KIIL HARRY SKIP | Officer | Sale | Sep 15, 2026 | 42,186 |
| MARINARO MICHAEL | President | Stock Award(Grant) | Nov 1, 2026 | 113,353 |
| MARTHA GEOFFREY S | Chief Executive Officer | Stock Award(Grant) | Aug 2, 2026 | 327,866 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.91% | 114,020,787 | 11.61B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.55% | 83,816,735 | 8.53B | Jun 29, 2026 |
| State Street Corporation | 4.96% | 63,399,315 | 6.45B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.66% | 34,059,967 | 3.47B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.36% | 30,192,015 | 3.07B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 2.17% | 27,784,471 | 2.83B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 40,757,422 | 4.15B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 33,271,457 | 3.39B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 17,056,298 | 1.74B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 16,635,418 | 1.69B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 15,820,582 | 1.61B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.96% | 12,221,643 | 1.24B | Jun 29, 2026 |